A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis

Large-cell carcinoma (LCC) of the lung is defined as an undifferentiated non-small cell lung cancer (NSCLC) and accounts for approximately 7.5% of lung cancers. Immune checkpoint inhibitors (ICIs) may be effective for LCC, but there has been no firm evidence due to its low frequency. We herein repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Ooi, Ryunosuke, Tobino, Kazunori, Sakabe, Mitsukuni, Kawabata, Takafumi, Hiramatsu, Yuri, Sueyasu, Takuto, Yoshimine, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481563/
https://www.ncbi.nlm.nih.gov/pubmed/32944497
http://dx.doi.org/10.1016/j.rmcr.2020.101197
_version_ 1783580631413817344
author Ooi, Ryunosuke
Tobino, Kazunori
Sakabe, Mitsukuni
Kawabata, Takafumi
Hiramatsu, Yuri
Sueyasu, Takuto
Yoshimine, Kohei
author_facet Ooi, Ryunosuke
Tobino, Kazunori
Sakabe, Mitsukuni
Kawabata, Takafumi
Hiramatsu, Yuri
Sueyasu, Takuto
Yoshimine, Kohei
author_sort Ooi, Ryunosuke
collection PubMed
description Large-cell carcinoma (LCC) of the lung is defined as an undifferentiated non-small cell lung cancer (NSCLC) and accounts for approximately 7.5% of lung cancers. Immune checkpoint inhibitors (ICIs) may be effective for LCC, but there has been no firm evidence due to its low frequency. We herein report an 80-year-old woman with LCC of the lung who was successfully treated with pembrolizumab but developed sclerosing cholangitis as an immune-related adverse event. This case highlights the efficacy of ICIs for LCC as well as the importance of the immediate and detailed management of ICI-related sclerosing cholangitis.
format Online
Article
Text
id pubmed-7481563
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74815632020-09-16 A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis Ooi, Ryunosuke Tobino, Kazunori Sakabe, Mitsukuni Kawabata, Takafumi Hiramatsu, Yuri Sueyasu, Takuto Yoshimine, Kohei Respir Med Case Rep Case Report Large-cell carcinoma (LCC) of the lung is defined as an undifferentiated non-small cell lung cancer (NSCLC) and accounts for approximately 7.5% of lung cancers. Immune checkpoint inhibitors (ICIs) may be effective for LCC, but there has been no firm evidence due to its low frequency. We herein report an 80-year-old woman with LCC of the lung who was successfully treated with pembrolizumab but developed sclerosing cholangitis as an immune-related adverse event. This case highlights the efficacy of ICIs for LCC as well as the importance of the immediate and detailed management of ICI-related sclerosing cholangitis. Elsevier 2020-08-25 /pmc/articles/PMC7481563/ /pubmed/32944497 http://dx.doi.org/10.1016/j.rmcr.2020.101197 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Ooi, Ryunosuke
Tobino, Kazunori
Sakabe, Mitsukuni
Kawabata, Takafumi
Hiramatsu, Yuri
Sueyasu, Takuto
Yoshimine, Kohei
A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis
title A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis
title_full A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis
title_fullStr A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis
title_full_unstemmed A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis
title_short A case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis
title_sort case of large-cell lung carcinoma successfully treated with pembrolizumab but complicated with cholangitis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481563/
https://www.ncbi.nlm.nih.gov/pubmed/32944497
http://dx.doi.org/10.1016/j.rmcr.2020.101197
work_keys_str_mv AT ooiryunosuke acaseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT tobinokazunori acaseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT sakabemitsukuni acaseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT kawabatatakafumi acaseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT hiramatsuyuri acaseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT sueyasutakuto acaseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT yoshiminekohei acaseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT ooiryunosuke caseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT tobinokazunori caseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT sakabemitsukuni caseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT kawabatatakafumi caseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT hiramatsuyuri caseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT sueyasutakuto caseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis
AT yoshiminekohei caseoflargecelllungcarcinomasuccessfullytreatedwithpembrolizumabbutcomplicatedwithcholangitis

Ejemplares similares